August 24, 2018 QUARTERLY REPORT – 2018 Q2
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q2...
July 11, 2018 Annual Report 2017
Posted at 10:15h
in Uncategorized
Vaccibody - Annual report 2017...
May 14, 2018 QUARTERLY REPORT – 2018 Q1
Posted at 10:00h
in Uncategorized
Vaccibody - Quarterly report 2018 Q1...
April 26, 2018 VACCIBODY AS ANNOUNCES STRONG KILLER T CELL RESPONSES (CD8+) in VB10.16 VACCINATED PATIENTS FURTHER STRENGTHENING THE STRONG POTENTIAL OF THEIR VACCINE TECHNOLOGY PLATFORM; PRESENTING AT EUROPEAN NEOANTIGEN SUMMIT AMSTERDAM
Posted at 10:00h
in Uncategorized
Vaccibody AS, a clinical-stage company focused on developing cancer vaccines to target solid tumors, today announces clinical data demonstrating vaccine-induced killer T cell responses (CD8+) in patients in their clinical program to treat precancerous cervical intraepithelial neoplasia (CIN) 2/3 lesions (VB C-01). President and Chief...
April 4, 2018 VACCIBODY AS ANNOUNCES INFORMED CONSENT SIGNED BY FIRST PATIENT AND ENROLMENT PROCESS INITIATED IN THE CANCER NEOANTIGEN PHASE I/IIA CLINICAL TRIAL.
Posted at 12:00h
in Uncategorized
Vaccibody AS, a clinical stage immunotherapy company focused on developing personalized neoantigen cancer vaccines to target solid tumors, today announces informed consent signed by the first patient and enrolment process initiated in the clinical trial. The patient will be enrolled in Heidelberg, Germany at the...
April 3, 2018 Vaccibody calls for Annual General Meeting.
Posted at 08:28h
in Uncategorized
Vaccibody calls for Annual General Meeting to be held on April 10, 2018 at 10.00 AM in Forskningsparken, Oslo. Shareholders will receive the call documents electronically or by post. The call documents can also be downloaded here....
March 8, 2018 VACCIBODY AS ANNOUNCES APPROVAL OF CLINICAL TRIAL APPLICATION (CTA) FOR ITS CANCER NEOANTIGEN PHASE I/IIA TRIAL BY GERMAN REGULATORY AUTHORITIES (PAUL EHRLICH INSTITUTE (PEI)).
Posted at 12:05h
in Uncategorized
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)). Dr. Martin Bonde, Chief Executive Officer...
March 1, 2018 VACCIBODY AS TO HOST CAPITAL MARKETS DAY IN OSLO ON 3rd APRIL 2018.
Posted at 09:45h
in Uncategorized
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, will host a capital markets day and invites analysts, brokers, investors and press to presentations by the members of the company’s executive management team and by Principal Investigator...
January 24, 2018 Vaccibody AS announces conditional approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)) as well as approval by the central ethics committee in Heidelberg (Ethikkommission Medizinische Fakultät Heidelberg); Reiterates estimate to start cancer neoantigen trial in Q1, 2018.
Posted at 10:00h
in Uncategorized
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces conditional approval of Clinical Trial Application (CTA) for its cancer neoantigen phase I/IIa trial by German regulatory authorities (Paul Ehrlich Institute (PEI)). The Company estimates that...
January 8, 2018 Vaccibody AS announces pre-clinical data showing improved ability to elicit strong killer T cell responses to neoantigens thus supporting the promise of their DNA vaccine platform for anti-cancer therapy; Attending JP Morgan in San Francisco.
Posted at 10:00h
in Uncategorized
Vaccibody AS, a clinical stage company focused on developing personalized neoepitope cancer vaccines to target solid tumors, today announces pre-clinical data supporting elicitation of strong killer T cell responses (CD8+ T cells) towards cancer neoantigens. The executive management is present at JP Morgan in San...